Smruthi Organics Ltd
Incorporated in 1989, Smruthi Organics Ltd
is a manufacturer of Active Pharmaceutical Ingredients[1]
- Market Cap ₹ 158 Cr.
- Current Price ₹ 138
- High / Low ₹ 182 / 103
- Stock P/E 44.3
- Book Value ₹ 62.6
- Dividend Yield 1.09 %
- ROCE 7.98 %
- ROE 5.04 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 0.86% over last quarter.
Cons
- The company has delivered a poor sales growth of -0.78% over past five years.
- Company has a low return on equity of 5.44% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
92 | 77 | 74 | 79 | 97 | 137 | 131 | 126 | 133 | 141 | 128 | 126 | |
90 | 72 | 63 | 69 | 94 | 121 | 116 | 98 | 115 | 131 | 116 | 114 | |
Operating Profit | 2 | 5 | 11 | 10 | 3 | 17 | 15 | 29 | 18 | 10 | 12 | 12 |
OPM % | 2% | 6% | 14% | 13% | 3% | 12% | 12% | 23% | 14% | 7% | 9% | 10% |
1 | 0 | 0 | 1 | 0 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | |
Interest | 5 | 6 | 5 | 4 | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 |
Depreciation | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 |
Profit before tax | -9 | -6 | 2 | 3 | -5 | 10 | 12 | 24 | 14 | 4 | 5 | 5 |
Tax % | -32% | -33% | 55% | 39% | -31% | 30% | 30% | 29% | 25% | 8% | 28% | 27% |
-6 | -4 | 1 | 2 | -3 | 7 | 8 | 17 | 10 | 4 | 4 | 4 | |
EPS in Rs | -5.39 | -3.34 | 0.63 | 1.39 | -2.82 | 6.02 | 7.41 | 14.95 | 9.07 | 3.61 | 3.14 | 3.11 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 20% | 33% | 55% | 48% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | -1% |
3 Years: | -2% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | -16% |
3 Years: | -30% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | -11% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 12% |
3 Years: | 5% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 11 | 11 | 11 | 11 | 11 |
Reserves | 31 | 26 | 27 | 28 | 25 | 33 | 39 | 49 | 56 | 57 | 58 | 60 |
43 | 45 | 37 | 33 | 31 | 28 | 16 | 10 | 3 | 6 | 12 | 17 | |
48 | 34 | 35 | 20 | 25 | 37 | 30 | 21 | 18 | 32 | 37 | 23 | |
Total Liabilities | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 |
41 | 35 | 32 | 30 | 30 | 30 | 32 | 31 | 33 | 37 | 40 | 45 | |
CWIP | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
83 | 72 | 69 | 54 | 54 | 69 | 56 | 60 | 53 | 66 | 77 | 64 | |
Total Assets | 126 | 109 | 103 | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 9 | 14 | 9 | 5 | 12 | 21 | 23 | 2 | 12 | 4 | 10 | |
-2 | -1 | 0 | -0 | -3 | -4 | -5 | -3 | 7 | -10 | -7 | -11 | |
-6 | -8 | -14 | -9 | -2 | -5 | -17 | -7 | -12 | -2 | 3 | 1 | |
Net Cash Flow | 2 | -1 | -0 | 0 | 0 | 2 | -1 | 13 | -3 | 0 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 102 | 103 | 95 | 97 | 95 | 97 | 68 | 62 | 78 | 96 | 117 | 94 |
Inventory Days | 133 | 123 | 166 | 145 | 126 | 92 | 75 | 100 | 91 | 96 | 150 | 151 |
Days Payable | 132 | 106 | 128 | 123 | 130 | 120 | 97 | 81 | 50 | 98 | 144 | 85 |
Cash Conversion Cycle | 104 | 120 | 133 | 119 | 92 | 68 | 46 | 80 | 118 | 93 | 123 | 160 |
Working Capital Days | 109 | 113 | 100 | 88 | 93 | 78 | 70 | 76 | 107 | 86 | 111 | 117 |
ROCE % | -5% | 0% | 9% | 10% | -1% | 21% | 25% | 39% | 21% | 7% | 8% | 8% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 7 May
- Revision In Record Date And Book Closure Date For AGM And Dividend 5 May
-
Integrated Filing (Financial)
5 May - Smruthi Organics reports FY25 audited profit Rs.356.28L, declares Rs.1.5/share dividend, unmodified audit opinion.
- The Dividend On Equity Shares For The Year Ended 31St March, 2025, As Recommended By The Board And As May Be Declared At The AGM, Will Be Paid To Those Shareholders Or Their Mandates: A) Whose Names Appear As Beneficial Owners As At The End Of The Business Hours On Friday, 13Th June, 2025, In The List Of Beneficial Owners To Be Furnished By National Securities Depository Limited And Central Depository Services (India) Limited In Respect Of The Shares Held In Electronic Form; And B) Whose Names Appear As Members In The Register Of Members Of The Company As At The End Of The Business Hours On Friday, 13Th June, 2025, After Giving Effect To Valid Request(S) Received For Transmission/Transposition Of Shares And Lodged With The Company/ Its Registrar & Share Transfer Agents On Or Before Friday, 13Th June, 2025. 5 May
- The Register Of Members & Share Transfer Book Will Remain Closed From 13Th June 2025 To 20Th June 2025 (Both Days Inclusive) For The Purpose Of AGM And Payment Of Dividend. 5 May
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
SOL is in the pharmaceutical business with presence in manufacturing bulk drugs and active pharmaceutical ingredients